USA – FDA offers strategies to streamline schizophrenia drug trials

Shortening the length of clinical trials and simplifying the symptom scale are two strategies that could help make schizophrenia drug trials less costly and more efficient, according to study findings from scientists at the U.S. Food and Drug Administration (FDA).

Schizophrenia drug developers face several obstacles when evaluating treatments, including high patient dropout rates in trials, modest treatment effects, high placebo response, and uncertainty about which endpoints capture the drug’s impact on disease symptoms.  “Given these obstacles, it may not be surprising that several larger pharmaceutical companies appear to have scaled back their developmental efforts in regard to schizophrenia, despite its toll on patients and their families,” the FDA wrote in a recent Regulatory Science Impact Story…